ZALTRAP

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Italy, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, Spain, Turkey, UK.

Active ingredients

The drug ZALTRAP contains one active pharmaceutical ingredient (API):

1	Aflibercept UNII 15C2VL427D - AFLIBERCEPT
	Aflibercept, also known as VEGF TRAP in the scientific literature, is a recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of the human IgG1. Aflibercept blocks the activation of VEGF receptors and the proliferation of endothelial cells, thereby inhibiting the growth of new vessels that supply tumours with oxygen and nutrients.
	Read more about Aflibercept

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZALTRAP Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XX44		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX44

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	502817040072707, 502817040072807, 576720050068217, 576720050068317
EE	Ravimiamet	1607251, 1607262, 1607273
ES	Centro de información online de medicamentos de la AEMPS	112814001, 112814003
FI	Lääkealan turvallisuus- ja kehittämiskeskus	125496, 152441
FR	Base de données publique des médicaments	60089217
GB	Medicines & Healthcare Products Regulatory Agency	222195, 222199
HK	Department of Health Drug Office	62551
IT	Agenzia del Farmaco	042689012, 042689024, 042689036
JP	医薬品医療機器総合機構	4291436A1023, 4291436A2020
LT	Valstybinė vaistų kontrolės tarnyba	1069238, 1069239, 1069240
NL	Z-Index G-Standaard, PRK	108383, 108391
PL	Rejestru Produktów Leczniczych	100037810
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69312001, W69312002, W69312003
SG	Health Sciences Authority	14592P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699809980020, 8699809980037, 8699809980044
US	FDA, National Drug Code	0024-5840, 0024-5841